Clinical trials: Non-Diabetic
Non-healing Wound, Non-healing Diabetic Foot Ulcer
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
It is hypothesized that application of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer will, with concomitant management of infection, result in a higher proportion…
- Conditions
- Non-healing Wound, Non-healing Diabetic Foot Ulcer, Diabetic Foot Infection
- Trial name
- NCT03230175
- Testing
- TTAX01, Surgical resection and debridement, Systemic antibiotics
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- BioTissue Holdings, Inc
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi
Obesity
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
- Trial name
- NCT02243202
- Testing
- Canagliflozin, Phentermine
- Where
- 17 sites in United States
- Volunteers
- 335 people
- Sponsor
- Janssen Research & Development, LLC
Diabetic Foot Ulcer
Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU).
- Trial name
- NCT01113515
- Testing
- Esmolol hydrochloride
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 44 people
- Sponsor
- Novalead Pharma Private Limited
Diabetes Mellitus, Type 2
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled…
- Trial name
- NCT00295633
- Testing
- Saxagliptin, pioglitazone, rosiglitazone
- Where
- 133 sites in United States, Argentina and 6 more
- Volunteers
- 565 people
- Sponsor
- AstraZeneca
Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Symptomatic NOH in patients with primary autonomic failure is thought to be a consequence of norepinephrine depletion leading to a diminished capacity to effect an appropriate cardiovascular response to an orthostatic challenge…
- Conditions
- Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency, Non-Diabetic Neuropathy, Neurogenic Orthostatic Hypotension
- Trial name
- NOH304 (NCT01132326)
- Testing
- Droxidopa
- Volunteers
- 350 people
- Sponsor
- Chelsea Therapeutics
Diabetic Peripheral Neuropathic Pain
A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)
The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as duloxetine in participants with diabetic peripheral neuropathic pain.
- Trial name
- NCT02417935
- Testing
- Duloxetine, Pregabalin
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
- Trial name
- NCT00374907
- Testing
- Saxagliptin, Metformin (blinded), Metformin (open-label)
- Where
- 3 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Diabetic Macular Edema (DME)
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.
- Trial name
- ILUMINATE (NCT02080091)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Alimera Sciences
Hyperglycemia
Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin
The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.
- Trial name
- HMH (NCT01136746)
- Testing
- Human regular insulin, Insulin lispro, Insulin glargine
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Non-diabetic Nephropathy
To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
The study is designed to primarily assess the effect of aliskiren on albuminuria in patients with non-diabetic nephropathy when treated with ramipril and volume intervention.
- Trial name
- ARIA (NCT01302899)
- Testing
- Aliskiren, Hydrochlorothiazide (HCTZ), Ramipril
- Where
- 2 sites in Netherlands
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Type 2 Diabetes Mellitus
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Primary Objective: To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24) Secondary Objective: To assess the effect of the 2 lixisenatide regimens on: The…
- Trial name
- NCT01517412
- Testing
- Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin
- Where
- 82 sites in United States, Canada and 8 more
- Volunteers
- 451 people
- Sponsor
- Sanofi
Hyperlipidemia
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
- Trial name
- PLANET II (NCT00296400)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 107 sites in United States, Brazil and 9 more
- Volunteers
- 237 people
- Sponsor
- AstraZeneca
Diabetic Foot Ulcer, Surgical Wound
The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers
A Multicentre Randomized Controlled Trial to Investigate the Effect of Natrox Topical Oxygen Wound Therapy on the Healing rates of Diabetic Foot Ulcers.
- Trial name
- NCT03905863
- Testing
- Natrox® Oxygen Wound Therapy
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 145 people
- Sponsor
- Inotec AMD Limited
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 4 (NCT04880850)
- Testing
- Insulin icodec, Insulin glargine, Insulin aspart
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Diabetic Retinopathy
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
- Trial name
- NCT05409235
- Testing
- OTT166, Vehicle control
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 225 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Antiplatelet Aggregation
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
The purpose of the study is to look at the biomarkers of inflammation and platelet activation in patients with drug eluting stents implanted approximately 12 months ago on aspirin and statin, for a 4-week period after the routine…
- Trial name
- DECADES (NCT00493779)
- Testing
- Blood Collection
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- Bristol-Myers Squibb
Anti- VGF Inhibitor, Diabetic Macular Edema
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
This study will asses sthe safety of pegaptanib sodium in patients with diabetic macular edema. The hypothesis is that pegaptanib is safe and efficacious in patients with diabetic macular edema.
- Conditions
- Anti- VGF Inhibitor, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT01189461
- Testing
- pegaptanib sodium
- Where
- 12 sites in Finland, Spain and 2 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company